Danoprevir (INN)[1] is an orally available[2] 15-membered macrocyclic peptidomimetic inhibitor of NS3/4A HCV protease.

Danoprevir is a clinical candidate based on its favorable potency profile against multiple HCV genotypes 1–6 and key mutants (GT1b, IC50 = 0.2–0.4 nM; replicon GT1b, EC50 = 1.6 nM).

In 2013, Danoprevir was licensed to Ascletis by Roche for development and production in China under the tradename Ganovo.

[7][8] Seiwert SD, Andrews SW, Jiang Y, Serebryany V, Tan H, Kossen K, et al. (December 2008).

"Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227)".